Arecor and Hikma expand collaboration to second product

The development uses Arecor’s proprietary drug formulation technology platform Arestat

Hikma Pharmaceuticals PLC -

Hikma Pharmaceuticals PLC (LON:HKMA) and private firm Arecor Limited have expanded their agreement to co-develop ready-to-administer injectable medicines in the US to a second product.

The new deal builds on an earlier agreement signed in January to develop a product using Arecor’s proprietary drug formulation technology platform Arestat.

Hikma is expected to file the product covered by this latest agreement for approval with the US Food and Drug Administration in 2023.

“We are pleased to expand on our partnership with Arecor and add a new ready-to-administer product to our growing pipeline of differentiated injectable medicines,” said Riad Mishlawi, President, Hikma Injectables in a statement.

“Arecor’s state-of-the-art technology platform is a perfect complement to Hikma’s strong manufacturing capabilities and excellent commercial team, with its broad relationships across US hospital systems. We look forward to continuing to work together to bring an important new treatment option to patients and healthcare providers in the US.”

Sarah Howell, Arecor’s chief executive added: “Our track record in developing ready-to-administer medicines is further strengthened by this second agreement with Hikma. This growing partnership supports both companies’ product development strategies to bring enhanced products to market that simplify care and improve patient outcomes.”  

Arecor will receive an upfront payment and further payments on the achievement of development, regulatory and commercial milestones.  

Hikma will be responsible for the manufacture and commercialisation of the product.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...


Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal

Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product. As Howell explains, this deal follows on from the first...

on 20/10/20

2 min read